Volume 15, Number 8—August 2009
Research
Increase in Pneumococcus Macrolide Resistance, United States
Stephen G. Jenkins
and David J. Farrell
and David J. FarrellTable 2
Macrolide resistance genotypes, year 5 (2004-2005) and year 6 (2005–2006) of the PROTEKT US surveillance study*
| Genotype | No. isolates (% of ERSP)† |
|
|---|---|---|
| Year 5 (n = 1,907) | Year 6 (n = 2,381) | |
| erm(B) | 310 (16.3) | 448 (18.8) |
| mef(A) | 1,172 (61.5) | 1,282 (53.8) |
| erm(B) + mef(A) | 377 (19.8) | 575 (24.1) |
| erm(TR) | 2 (0.1) | 0 |
| Ribosomal mutations | 26 (1.4) | 41 (1.7) |
*PROTEKT US, Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin, United States; ERSP, erythromycin-resistant Streptococcus pneumoniae.
†A total of 20 isolates in year 5 and 35 isolates in year 6 were not viable for genotyping.
